OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

Q&A with OCRFA Grantee Hui Shen, Ph.D.

Hui Shen, Ph.D. Q&A with Hui Shen, Ph.D. Van Andel Research Institute 2016 Liz Tilberis Early Career Award   OCRFA: Tell us about yourself. Dr. Shen: My name is Hui Shen. I am originally from China, and had lived in Hong Kong and Los Angeles before calling Michigan home. In terms of hobbies... 

Kiehl’s Since 1851 Celebrates LifeRide for Ovarian Cancer Research Fund Alliance

Finale Event Celebrated at Kiehl’s Santa Monica on September 22 WHO: Kiehl’s President Chris Salgardo OCRFA President and CEO Audra Moran LifeRider Scott Patterson LifeRider Gilles Marini LifeRider Luke Wessman LifeRider Grant Reynolds …And special guests, including: Alyssa Milano Amanda Ensing ... 

Research Round-Up: 11th Biennial Ovarian Cancer Research Symposium September 12-13, 2014 in Seattle, Washington

By Annie Ellis Ovarian Cancer survivor and advocate, OCRFA Scientific Advisory Committee Member The Biennial Ovarian Cancer Research Symposium is presented by the Rivkin Center for Ovarian Cancer and the American Association for Cancer Research. The goal of the Symposium is to bring together clinicians... 

Wheels Up Announces WHEELS UP CARES Philanthropy Program; Introduces First-Ever Teal Beechcraft King Air 350i Airplane in Support of Ovarian Cancer

Teal Plane Joins the Wheels Up Pink Plane NEW YORK, Sept. 12, 2016 /PRNewswire/ — Wheels Up Founder and CEO Kenny Dichter today announced the launch of WHEELS UP CARES, a philanthropic initiative to raise awareness and funds for a cause important to the Company, and its members. Through the WHEELS... 

2016 Woman to Woman Grantees Announced

OCRFA is pleased to announce the recipients of 2016 Woman to Woman grants. Woman to Woman is a network of trained volunteers—survivors of gynecologic cancer—that provide hope, support and education to women in treatment for ovarian and other gynecologic cancers in a variety of settings. Woman to... 

Oral Contraceptives Play Role in Decline of Deaths from Ovarian Cancer

(September 12, 2016) The European Society of Medical Oncology published a study last week that indicated the reasons for a decrease in deaths from ovarian cancer in both young women and post-menopausal women. From 2002 to 2012, death rates fell by 10% in the European Union and by 16% in the United States,... 

Study Reveals Potential Importance of Studying Cell Lineage

(September 9, 2016) Nature Communications recently published a study that used proteomics, or the study of proteins, to identify the lineage of 26 different ovarian cancer cell lines. Identifying where the cell lines originate can help us categorize a full spectrum of tumors and lead us to understand... 

OCRFA Applauds Food and Drug Administration’s Statement on Ovarian Cancer Screening Test

For Immediate Release September 7, 2016 Contact: Lisa Mauti lmauti@ocrfa.org 443-845-2626 Today the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated. The FDA states, “despite extensive research... 

September is Ovarian Cancer Awareness Month #30DaysofTeal

Follow OCRFA on Facebook, Twitter and Instagram, share, and join the conversation at #30DaysofTeal! September 26: Family history also contributes to a woman’s risk of ovarian cancer. Women who have one first-degree relative with ovarian cancer but no known genetic mutation still have an increased... 

SGO and ASCO Agree on Guidelines for Common Type of Ovarian Cancer

(August 16, 2016) While primary cytoreductive surgery followed by chemotherapy is the standard of care for newly diagnosed women with advanced ovarian cancer, newly issued practice guidelines suggest that some patients may benefit more from first-line neoadjuvant chemotherapy (NACT) and followed by surgery. Last...